Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary bone lymphoma: experience with 52 patients.

Pier Luigi Zinzani1, Giovanna Carrillo, Stefano Ascani

  • 1Istituto di Ematologia e Oncologia Medica L. & A. Seràgnoli, Policlinico S. Orsola, via Massarenti 9, 40138 Bologna, Italy. plzinzo@med.unibo.it

Haematologica
|March 26, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BRG1-mediated suppression of ferroptosis underlies BTK inhibitor resistance.

Nature communications·2026
Same author

Sponge-like sonographic pattern of the spleen in immune dysregulation disorders.

Frontiers in immunology·2026
Same author

Lymphoproliferation in inborn errors of immunity: From challenging diagnosis to histologic revision.

Journal of human immunity·2026
Same author

Impact of baseline osseous involvement on outcomes in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Blood neoplasia·2026
Same author

B-cell and plasma cell proliferations associated with T follicular helper cell lymphomas: clinical-pathological and genetic features.

Virchows Archiv : an international journal of pathology·2026
Same author

Modern and multidisciplinary care in polycythemia vera.

Annals of hematology·2026

Chemotherapy or combined-modality therapy offers more durable complete responses for primary bone lymphomas (PBL) than radiation therapy alone. This approach significantly reduces relapse rates in PBL patients.

Area of Science:

  • Oncology
  • Hematology
  • Bone Malignancies

Background:

  • Non-Hodgkin's primary bone lymphomas (PBL) are rare malignancies.
  • Treatment efficacy for PBL has historically varied.
  • Optimal therapeutic strategies require further investigation.

Purpose of the Study:

  • To retrospectively analyze the efficacy of different treatment modalities for primary bone lymphomas (PBL).
  • To compare outcomes between chemotherapy (with/without radiation) and radiation therapy alone in PBL patients.

Main Methods:

  • Retrospective analysis of 52 previously untreated PBL patients diagnosed between 1982 and 1998.
  • Review of patient presentation, clinical course, histology, and immunohistochemical stains.
  • Comparison of treatment outcomes based on therapeutic approach.

Related Experiment Videos

Main Results:

  • Complete response (CR) rates were 85% with chemotherapy (with/without radiation) versus 64% with radiation alone.
  • Relapse rates were significantly lower after chemotherapy (6%) compared to radiation alone (57%) (p = 0.004).
  • Front-line therapeutic approach (chemotherapy vs. radiation alone) was a significant prognostic factor.

Conclusions:

  • Chemotherapy or combined-modality therapy appears superior for achieving durable complete responses in PBL.
  • Radiation therapy alone is associated with a higher risk of relapse in PBL.
  • Current data suggest chemotherapy-based approaches are preferred for PBL management.